Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy
AuthorsStick, L. B.
Lorenzen, E. L.
Yates, E. S.
Anandadas, Carmel N
Kirby, A. M.
Kirova, Y. M.
Nielsen, M. M. B.
Nissen, H. D.
Offersen, B. V.
AffiliationDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
MetadataShow full item record
AbstractBackground and purpose: Adjuvant radiotherapy of internal mammary nodes (IMN) improves survival in high-risk early breast cancer patients but inevitably leads to more dose to heart and lung. Target coverage is often compromised to meet heart/lung dose constraints. We estimate heart and lung dose when target coverage is not compromised in consecutive patients. These estimates are used to guide the choice of selection criteria for the randomised Danish Breast Cancer Group (DBCG) Proton Trial. Materials and methods: 179 breast cancer patients already treated with loco-regional IMN radiotherapy from 18 European departments were included. If the clinically delivered treatment plan did not comply with defined target coverage requirements, the plan was modified retrospectively until sufficient coverage was reached. The choice of selection criteria was based on the estimated number of eligible patients for different heart and lung dose thresholds in combination with proton therapy capacity limitations and dose-response relationships for heart and lung. Results: Median mean heart dose was 3.0 Gy (range, 1.1-8.2 Gy) for left-sided and 1.4 Gy (0.4-11.5 Gy) for right-sided treatment plans. Median V17Gy/V20Gy (hypofractionated/normofractionated plans) for ipsilateral lung was 31% (9-57%). The DBCG Radiotherapy Committee chose mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37% as thresholds for inclusion in the randomised trial. Using these thresholds, we estimate that 22% of patients requiring loco-regional IMN radiotherapy will be eligible for the trial. Conclusion: The patient selection criteria for the DBCG Proton Trial are mean heart dose ≥ 4 Gy and/or lung V17Gy/V20Gy ≥ 37%.
CitationStick LB, Lorenzen EL, Yates ES, Anandadas C, Andersen K, Aristei C, et al. Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy. Clin Transl Radiat Oncol. 2021;27:126-31.
JournalClinical and Translational Radiation Oncology
- Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial.
- Authors: Thomsen MS, Berg M, Zimmermann S, Lutz CM, Makocki S, Jensen I, Hjelstuen MHB, Pensold S, Hasler MP, Jensen MB, Offersen BV
- Issue date: 2021 May
- The potential benefits from respiratory gating for breast cancer patients regarding target coverage and dose to organs at risk when applying strict dose limits to the heart: results from the DBCG HYPO trial.
- Authors: Berg M, Lorenzen EL, Jensen I, Thomsen MS, Lutz CM, Refsgaard L, Nissen HD, Offersen BV
- Issue date: 2018 Jan
- CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects.
- Authors: Thorsen LB, Thomsen MS, Berg M, Jensen I, Josipovic M, Overgaard M, Overgaard J, Skogholt P, Offersen BV, Danish Breast Cancer Cooperative Group Radiotherapy committee.
- Issue date: 2014 Aug
- Quality assurance of conventional non-CT-based internal mammary lymph node irradiation in a prospective Danish Breast Cancer Cooperative Group trial: the DBCG-IMN study.
- Authors: Thorsen LB, Thomsen MS, Overgaard M, Overgaard J, Offersen BV, Danish Breast Cancer Cooperative Group Radiotherapy Committee.
- Issue date: 2013 Oct
- Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk.
- Authors: Hjelstuen MH, Mjaaland I, Vikström J, Dybvik KI
- Issue date: 2012 Mar